Risk of Development of the Metabolic Syndrome After Orthotopic Liver Transplantation

Ruiz-Rebollo, María Lourdes; Sánchez-Antolín, Gloria; García-Pajares, Félix; Fernández-Orcajo, P.; González-Sagrado, Manuel; Cítores-Pascual, Miguel Ángel; Velicia-Llames, R.; Caro-Patón, A.

doi:10.1016/j.transproceed.2010.02.018

Cited by 21 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in liver transplant patients it is considerably higher, approximately 40-50% (Laryea et al, 2007;Bianchi et al, 2008), though these percentages can vary according to geographical area, and are slightly lower, for example, in the Spanish population, both transplanted and non-transplanted (Ruiz-Rebollo et al, 2010).…”

Section: American Heart Association International Diabetes Federationmentioning

confidence: 94%

Metabolic Syndrome After Liver Transplantation

González‐Grande¹,

Jiménez‐Pérez²,

Sáez-Gómez³

et al. 2012

Liver Transplantation - Technical Issues and Complications

View full text Add to dashboard Cite

Section: American Heart Association International Diabetes Federationmentioning

confidence: 94%

Metabolic Syndrome After Liver Transplantation

González‐Grande¹,

Jiménez‐Pérez²,

Sáez-Gómez³

et al. 2012

Liver Transplantation - Technical Issues and Complications

View full text Add to dashboard Cite

“…Pre-transplant diabetes was found to predict PTMS in multiple series [18,20,24]. In fact, in one study, persons with pre-transplant diabetes had nearly 6 fold higher odds of having the MS after transplant [20].…”

Section: Pre-transplant Diabetesmentioning

confidence: 97%

“…Another point is that the reasons for LTx were different in all the studies; just one study analyzed metabolic alterations following HCV recurrence after LTx [24]. It is well known that HCV infection is related to insulin-resistance, so it would be better to separately investigate all patients with HCV infection, who may already have metabolic alterations before LTx [25].…”

Section: Review Of the Literaturementioning

confidence: 99%

“…Both pre-transplant weight [21] and Body Mass Index (BMI) [18,20,24] were correlated with PTMS. The rate of obesity in wait-listed patients varies by transplant indication.…”

Section: Obesitymentioning

confidence: 99%

“…However, data are mixed. The overall change in BMI after transplant was associated Body mass index (18,20,24) Cryptogenic cirrhosis (20,21) Alcoholic cirrhosis (21) Hepatitis C cirrhosis [21] Pretransplant diabetes (1820, 24) Age (20,21) Miscellaneous (triglycerides, high density lipoprotein (20) with the MS in one series [18] but not in another [20]. It is possible that pre-transplant ascites may result in the underestimation of weight gain post-transplant in the later series.…”

Section: Post-transplant Risk Factorsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the Literature

Pinna¹,

Pagotto²

2015

Endocrinol Metab Syndr

View full text Add to dashboard Cite

The clinical features of the Metabolic Syndrome (MS) as risk factors for transplantation have been cited separately and extensively in the transplant literature. There are few studies in literature evaluating the prevalence of MS before and after solid organ transplantation.MS puts transplant patients at risk in in two ways: 1) MS is one more risk factor to be considered in the pretransplantation workup; and 2) the combined risk of cardiovascular disease post-transplantation as a side effect of immunosuppressive medication together with the risk from cardiovascular disease stemming from the MS might put a post-transplantation patient at vastly increased risk for a cardiovascular event.There are several reports on the treatment of MS expecially after transplantation; from lifestyle changes to drug therapies. However, to now, guidelines about management of these patients are lacking.

show abstract

De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations

2021

View full text Add to dashboard Cite

BaCKgRoUND aND aIMS: Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, to aid in optimizing potential posttransplant screening practices. appRoaCH aND ReSUltS: Data from the United Network for Organ Sharing database of all adult livertransplant recipients from 1997 to 2017 were analyzed and a comparison made with cancer incidence from general population data using Surveillance, Epidemiology, and End Results data. Of 866 de novo GI malignancies, 405 colorectal and 216 pancreas were identified. The highest cumulative incidence for colorectal cancer occurred in recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females >50 years with alcohol-associated liver disease and HCC/CCA, with risk increasing above the general population within 5 years of transplant. Patients with PSC and HCC/CCA or NASH and HCC/CCA have the highest cumulative incidence of pancreatic cancer also rising within 5 years following transplant, with those patients >50 years old conferring the highest risk.CoNClUSIoNS: These data identify a high-risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol-associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher-risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver-transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest-risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.

show abstract

Risk of Development of the Metabolic Syndrome After Orthotopic Liver Transplantation

Cited by 21 publications

References 7 publications

Metabolic Syndrome After Liver Transplantation

Metabolic Syndrome After Liver Transplantation

Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the Literature

De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations

Contact Info

Product

Resources

About